3B Blackbio DX Ltd Q1 FY27 results (latest), Apr–Jun 2026 →See revenue, profit and what management said. You are viewing Q3 FY24.
3B

3B Blackbio DX Ltd

Q3 FY24Healthcare Services

3B Blackbio DX Q3 FY24 earnings call: Revenue & Margins

Q3 FY24 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹18Cr
+20% YoY
−5.3% QoQ
Net profit
₹9Cr
+12.5% YoY
+12.5% QoQ
Margin
50%
0 pp YoY
+9 pp QoQ

Based on 3B Blackbio DX Ltd's Q3 FY24 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹1,406
Market cap₹1.1K Cr
P/E20.4

The short version

Q3 FY 2023-24 Diagnostics Business Revenue: ₹1,531.37 lakh (including ₹11.63 lakh COVID sales) vs ₹1,043.99 lakh in Q3 FY 2022-23; over 30% effective growth YoY (Page 15). Q3 FY 2023-24 EBITDA: ₹1,004.31 lakh vs ₹1,170.47 lakh in Q3 FY 2022-23 (YoY decrease) - Q3 FY 2023-24 Profit After Tax (PAT): ₹769.37 lakh vs ₹873.96 lakh in Q3 FY 2022-23 (YoY decrease) - Revenue fr

From 3B Blackbio DX Ltd's Q3 FY24 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3 FY 2023-24 Diagnostics Business Revenue: ₹1,531.37 lakh (including ₹11.63 lakh COVID sales) vs ₹1,043.99 lakh in Q3 FY 2022-23; over 30% effective growth YoY (Page 15).
  • Export sales for molecular diagnostic kits in Q3 FY 2023-24: ₹267.20 lakh vs ₹219.89 lakh in Q3 FY 2022-23 (Page 15).
  • Consolidated Q3 FY 2023-24 Total Revenue: ₹2,029.65 lakh vs ₹1,760.85 lakh in Q3 FY 2022-23 (Page 5).
  • Consolidated Q3 FY 2023-24 Profit Before Tax: ₹1,115.20 lakh vs ₹989.68 lakh in Q3 FY 2022-23 (Page 5).
  • Consolidated Q3 FY 2023-24 Profit After Tax: ₹851.69 lakh vs ₹771.40 lakh in Q3 FY 2022-23 (Page 5).

2 more points from 3B Blackbio DX Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 25).
  • The amalgamation scheme with 3B BlackBio Biotech India Ltd is completed, creating a merged entity 3B BlackBio Dx Ltd, which is fully functional (Page 25).
  • The UK subsidiary, TRUPCR® Europe Limited in Manchester, has moved to a larger, state-of-the-art facility with dedicated labs for Production, QC, R&D, and storage/dispatch (Page 20).

2 more points from 3B Blackbio DX Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what 3B Blackbio DX Ltd said on order book & pipeline — free account, 30 seconds.

3B Blackbio DX Ltd — Quarterly revenue & net profit

Revenue Net profit
Sep 2024Q2 FY25
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26

3B Blackbio DX Ltd Q3 FY24 results — key figures

3B Blackbio DX Ltd Q3 FY24 reported results vs Q3 FY23, ₹ crore
₹ CrQ3 FY24Q3 FY23YoYQ2 FY24QoQ
Revenue1815+20%19-5.3%
Operating profit (EBITDA)97+28.6%8+12.5%
Operating margin50%50%0 pp41%+9 pp
Profit before tax1110+10%10+10%
Net profit (PAT)98+12.5%8+12.5%
EPS (₹)10.168.96+13.4%10.46-2.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were 3B Blackbio DX Ltd Q3 FY24 results?

Q3 FY 2023-24 Diagnostics Business Revenue: ₹1,531.37 lakh (including ₹11.63 lakh COVID sales) vs ₹1,043.99 lakh in Q3 FY 2022-23; over 30% effective growth YoY (Page 15). Q3 FY 2023-24 EBITDA: ₹1,004.31 lakh vs ₹1,170.47 lakh in Q3 FY 2022-23 (YoY decrease) - Q3 FY 2023-24 Profit After Tax (PAT): ₹769.37 lakh vs ₹873.96 lakh in Q3 FY 2022-23 (YoY decrease) - Revenue fr

What is 3B Blackbio DX Ltd share price analysis?

3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.

Is 3B Blackbio DX Ltd planning capital expenditure?

The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 25).

Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.